Abstract | BACKGROUND: Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome. OBJECTIVE: METHODS: Patients (aged 18 to 65 years) with International Headache Society-defined migraine with or without aura were enrolled in one of two identically designed, randomized, double-blind, parallel group, placebo-controlled studies. Patients treated a single migraine within 1 hour of onset of migraine head pain and while the pain was mild with either sumatriptan/naproxen or placebo. The primary efficacy measure was the percentage of patients who became pain-free 2 hours postdose. RESULTS: CONCLUSION: The fixed-dose single- tablet formulation of sumatriptan/naproxen was effective and well tolerated in an early intervention paradigm for the acute treatment of migraine, including traditional and nontraditional symptoms.
|
Authors | S D Silberstein, L K Mannix, J Goldstein, J R Couch, S C Byrd, M H Ames, S A McDonald, S E Lener, Cynthia Toso |
Journal | Neurology
(Neurology)
Vol. 71
Issue 2
Pg. 114-21
(Jul 08 2008)
ISSN: 1526-632X [Electronic] United States |
PMID | 18606965
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
- Migraine Disorders
(drug therapy)
- Naproxen
(administration & dosage, adverse effects)
- Nausea
(chemically induced)
- Sumatriptan
(administration & dosage, adverse effects)
- Treatment Outcome
|